The US Food and Drug Administration (FDA) has granted Fast Track Designation for HAYA Therapeutics’ HTX-001 for the treatment of symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM). The first-in-class investigational long non-coding RNA (lncRNA)-targeting therapy is in a Phase Ia/b trial, with the first cohort dosed this past May. HTX-001 is a… Read More
HAYA Therapeutics has dosed the first cohort in a Phase I trial evaluating a treatment for nonobstructive hypertrophic cardiomyopathy (nHCM). The Swiss biotechnology company is studying HTX-001, a differentiated and potentially disease-modifying approach to treating patients with nHCM. The investigational molecule is an antisense oligonucleotide… Read More
Eli Lilly and biotechnology company HAYA Therapeutics have announced a multi-year agreement to apply HAYA’s RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions. The partners aim to identify multiple regulatory genome derived RNA-based drug targets to address these… Read More
Following the release of Clarivate’s report ‘RNA Technology Companies to Watch’, DDW’s Diana Spencer speaks to Strand Therapeutics’ Jacob Becraft and HAYA Therapeutics’ Samir Ounzain to find out how this technology could revolutionise disease treatment. Therapies that act upon or incorporate RNA to fight disease have… Read More
